Globalstar vs ResMed Inc. — how do they compare? Globalstar trades at $83.82 (market cap $10.78B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 3× Globalstar's market cap, and ResMed Inc. pays a 1.16% dividend while Globalstar pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 21 Days and ResMed Inc. for 51 Days on average.
| GSAT | RMD | |
|---|---|---|
Market Cap | $10.78B | $31.89B |
Volume | 723,953 | 618,314 |
Sector | Media | Health |
52-Week High | $84.43 | $277.88 |
52-Week Low | $41.54 | $182.82 |
Typical Hold Time | 21 Days | 51 Days |
Enterprise Value | $10.79B | $31.24B |
Dividend Yield | — | 1.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Trailing returns across standard periods
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →